1. Indications

• Gastrointestinal: Management of acute diarrhea (reduces duration and stool frequency), prevention and treatment of Antibiotic-Associated Diarrhea (AAD), and as an H. pylori adjunct to increase eradication rates and reduce triple-therapy side effects.
• Oral & ENT Health: Treatment of halitosis and gingivitis via neutralization of volatile sulfur compounds (VSCs) and inhibition of oral biofilms.
• Respiratory Support: Provides topical and systemic support for pharyngeal mucosal immunity, effectively reducing the duration and severity of URTI and sore throat symptoms.

2. Technical Process (Iprona IPT)

• Solvent-Free Extraction: The flavor-masking components are created using Iprona Polyphenol Technology (IPT), which utilizes a solvent-free mechanical ultrafiltration process.
• Clean Label Standard: This mechanical process appeals to the demand for high-purity, medical-grade pediatric supplements without chemical processing agents.
• Biological Compliance: The technology produces standardized fruit extracts specifically designed to overcome the Increased Perception Threshold (IPT) in children, who biologically reject bitter or metallic tastes.

3. Clinical Advantages

• Proven Synergy: A 2024 randomized controlled trial demonstrated that children receiving the combination of probiotics plus Zinc recovered significantly faster than those on probiotics alone.
• "No-Gap" Dosing: Because S. boulardii is a yeast (eukaryotic), it is naturally resistant to antibacterials. It can be taken at the exact same time as an antibiotic, ensuring immediate protection and better patient compliance.
• Topical Defense: Unlike systemic-only treatments, the Zinc in this formulation acts as a topically active antimicrobial, providing localized defense against oral and pharyngeal pathogens.

4. Use & Dosage

• Adults: 1–2 sachets, taken twice daily.
• Children (>3 months): 1 sachet, taken twice daily.
• Standardization: This is a WHO-recommended dose for pediatric diarrhea.

5. Contraindications

• Central Venous Catheter (CVC): Prolactor BDii should not be used in patients with a CVC due to the rare risk of fungemia.
• Immunocompromised: It is contraindicated for severely immunocompromised patients.

6. Potential Side Effects & Drug Interactions

• Fungemia Risk: A documented, though rare, risk in high-risk populations (CVC or immunocompromised).
• Antifungals: Oral antifungals (e.g., Nystatin, Fluconazole) will neutralize the probiotic yeast.
• Antibiotic Interference: High-dose Zinc can interfere with the absorption of Quinolones or Tetracyclines; a 2-hour window is recommended for these specific drugs.

7. Sachet Advantage

• The sachet powder form is clinically superior to capsules for ENT and oral health because it ensures direct topical contact with the mouth and throat tissues.
• This localized delivery is essential for Zinc to effectively support pharyngeal mucosal immunity and act as an antimicrobial against gingivitis and sore throat bacteria while remaining easy for children to swallow.

FAQ